Cargando…
National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test lab...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392952/ https://www.ncbi.nlm.nih.gov/pubmed/34594859 http://dx.doi.org/10.46234/ccdcw2021.072 |
_version_ | 1783743621537726464 |
---|---|
author | Ou, Xichao Xia, Hui Wang, Shengfen Zhao, Bing Fan, Jiale Song, Yuanyuan Zhou, Yang Zheng, Yang Zhao, Yanlin |
author_facet | Ou, Xichao Xia, Hui Wang, Shengfen Zhao, Bing Fan, Jiale Song, Yuanyuan Zhou, Yang Zheng, Yang Zhao, Yanlin |
author_sort | Ou, Xichao |
collection | PubMed |
description | What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test laboratories’ proficiency for molecular TB diagnostic assays throughout the TB laboratory network. A total of 6 PT rounds for molecular diagnostics were conducted by NTRL from 2014 to 2019. What is added by this report? PT conducted using artificial sputum specimens increased from 120 in the first round to 1,835 in the sixth round. Overall, laboratories demonstrated good proficiency for MTB and drug-resistance detection by molecular diagnostics, which is evident from the qualification rates over the six rounds: 95%, 97%, 96%, 93%, 93%, and 97%, respectively. What are the implications for public health practice? The use of artificial sputum specimens for PT panel production to test TB molecular diagnostics in China is feasible. Most of the participating laboratories provided reliable molecular diagnostic results for MTB and drug-resistance detection. The TB laboratory network can be instrumental in implementing PT expansion and improving the quality of TB molecular diagnosis in China. |
format | Online Article Text |
id | pubmed-8392952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-83929522021-09-29 National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 Ou, Xichao Xia, Hui Wang, Shengfen Zhao, Bing Fan, Jiale Song, Yuanyuan Zhou, Yang Zheng, Yang Zhao, Yanlin China CDC Wkly Preplanned Studies What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test laboratories’ proficiency for molecular TB diagnostic assays throughout the TB laboratory network. A total of 6 PT rounds for molecular diagnostics were conducted by NTRL from 2014 to 2019. What is added by this report? PT conducted using artificial sputum specimens increased from 120 in the first round to 1,835 in the sixth round. Overall, laboratories demonstrated good proficiency for MTB and drug-resistance detection by molecular diagnostics, which is evident from the qualification rates over the six rounds: 95%, 97%, 96%, 93%, 93%, and 97%, respectively. What are the implications for public health practice? The use of artificial sputum specimens for PT panel production to test TB molecular diagnostics in China is feasible. Most of the participating laboratories provided reliable molecular diagnostic results for MTB and drug-resistance detection. The TB laboratory network can be instrumental in implementing PT expansion and improving the quality of TB molecular diagnosis in China. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021-03-19 /pmc/articles/PMC8392952/ /pubmed/34594859 http://dx.doi.org/10.46234/ccdcw2021.072 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Preplanned Studies Ou, Xichao Xia, Hui Wang, Shengfen Zhao, Bing Fan, Jiale Song, Yuanyuan Zhou, Yang Zheng, Yang Zhao, Yanlin National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title | National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title_full | National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title_fullStr | National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title_full_unstemmed | National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title_short | National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 |
title_sort | national proficiency testing of molecular diagnostics for tuberculosis and drug resistance detection — china, 2014–2019 |
topic | Preplanned Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392952/ https://www.ncbi.nlm.nih.gov/pubmed/34594859 http://dx.doi.org/10.46234/ccdcw2021.072 |
work_keys_str_mv | AT ouxichao nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT xiahui nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT wangshengfen nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT zhaobing nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT fanjiale nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT songyuanyuan nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT zhouyang nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT zhengyang nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 AT zhaoyanlin nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019 |